ILU Stock Chart & Stats
€112.64
-€0.44(-0.33%)
At close: 4:00 PM EST
€112.64
-€0.44(-0.33%)
Day’s Range― - ―
52-Week Range€77.67 - €173.94
Previous CloseN/A
Volume3.00
Average Volume (3M)48.00
Market Cap
€25.17B
Enterprise Value€19.51K
Total Cash (Recent Filing)€1.16B
Total Debt (Recent Filing)€2.54B
Price to Earnings (P/E)34.8
Beta0.54
Next Earnings
Jul 30, 2026EPS Estimate
1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.54
Shares Outstanding151,300,000
10 Day Avg. Volume64
30 Day Avg. Volume48
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€150.47Price Target Upside33.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)4.57
Revenue Forecast (FY)€4.00B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Razor-and-bladesIllumina's consumables-driven 'razor-and-blades' model creates durable recurring revenue tied to installed instruments. With TTM operating cash flow ~$1.13B and FCF ~$0.99B, this high-conversion cash profile supports predictable cash generation, funding operations and strategic initiatives over months.
Installed-base Shift To NovaSeq XRapid NovaSeq X adoption materially upgrades installed capacity and sequencing throughput, increasing consumables pull-through. Higher GB output (>30% YoY) and growing instrument placements improve long-term volume trajectory and unit economics, supporting sustainable margin expansion as the base converts to newer flow cells.
Strong Cash Generation And Capital FlexibilityConsistent free cash flow and a solid cash balance provide durable financial flexibility to fund scaling, M&A (SomaLogic closed), and shareholder returns. Robust cash conversion reduces reliance on external financing and supports execution on multi-quarter investments to resolve supply and capacity constraints.
Bears Say
Research & Applied Consumables WeaknessSustained weakness in research & applied consumables, driven by funding caution, reduces one of Illumina's core recurring growth engines. With revenue essentially flat in recent years, prolonged research softness limits durable top-line growth and makes margin gains more reliant on clinical adoption and cost improvements.
Microarrays Business DeclineA sharp RoW organic decline in microarrays signals secular or customer-specific deterioration in a legacy product line, reducing revenue diversification. Persistent microarray contraction raises risk that some legacy revenue pools won't reaccelerate, pressuring overall topline resilience over coming quarters.
NovaSeq X Supply Constraints And Margin DragDemand outpacing supply requires investment to scale production, creating near-term instrument revenue variability and higher costs. Management flagged Q2 margin headwinds and a phased H2 improvement; until capacity ramps, supply constraints and scaling costs can delay durable margin and revenue benefits from the installed-base transition.
Illumina News
ILU FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was €77.67 and its highest was €173.94 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is €25.17B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Jul 30, 2026 which is tomorrow.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Apr 30, 2026. The company reported €1.01 earnings per share for the quarter, beating the consensus estimate of €0.926 by €0.083.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.08.
How many shares outstanding does Illumina have?
Illumina has 151,300,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of €1.01 in its last earnings report, beating expectations of €0.926. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in DE:ILU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€150.47 (33.58% Upside)
€150.47 (33.58% Upside)
Blogger Sentiment
Bullish
DE:ILU Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €128.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.10%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILU Company Deck
ILU Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a clear beat in Q1 with multiple key operational and financial positives: revenue and EPS outperformance, strong clinical consumables growth (~20% ex-China), robust NovaSeq X placements (80+ in the quarter), margin expansion, and an upwardly revised full-year guide. Offsetting items include continued weakness in research & applied consumables (down ~12% ex-China), a 20% decline in microarrays RoW organic, supply constraints on NovaSeq X that require scaling investments, and near-term inflationary pressures impacting Q2 margins. Management framed the negatives as transitory or manageable and emphasized product innovation, strong cash flow, and progress toward 2027 targets.View all DE:ILU earnings summariesILU Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
ILU Stock 12 Month Forecast
Average Price Target
€150.47
▲(33.58% Upside)